INS and Hyperglycemia: Over 2 years, the risk of minor hypoglycaemia was significantly lower with liraglutide than glimepiride, consistent with GLP-1 receptor agonists stimulating insulin secretion in a glucose-dependent manner (i.e. only during hyperglycaemia) compared with SUs stimulating secretion of insulin at any blood glucose concentration.